Amorphous solid dispersions (ASDs) are advanced pharmaceutical formulations in which a poorly water-soluble drug is dispersed within an amorphous polymer matrix. In this non-crystalline form, the drug exhibits enhanced apparent solubility. While various polymers can be considered, the optimal polymer must effectively maintain supersaturation by inhibiting drug crystallization.
Watch our webinar ‘Polymer Screening for Amorphous Solid Dispersions (ASDs) using the Crystal16’ by Veranova’s Principal Scientist, Thierry Bonnaud.
In this webinar, hosted by Technobis, Thierry demonstrates the application of the solvent shift method as a preliminary screening tool to reduce the number of polymers selected for further evaluation. Piroxicam, a BCS Class II non steroidal anti-inflammatory drug (NSAID) with low aqueous solubility, was used as the model compound. The use of the Crystal16 system in screening polymers for piroxicam with the solvent shift method is discussed in detail.
